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Abstract
Background: Risk factors underlying the development and progression of some of the less well-
recognised complications of type 2 diabetes, including cognitive impairment and non-alcoholic fatty
liver disease, are poorly understood. The Edinburgh Type 2 Diabetes Study was established in 2006
in order to investigate the role of potential risk factors in these complications, as well as to further
investigate mechanisms underlying the development and progression of micro and macrovascular
disease in type 2 diabetes.
Methods and design: The study is designed as a prospective cohort study. Participants recruited
at baseline (2006–2007) constitute 1066 men and women aged 60 to 75 years with established type
2 diabetes, living in the Lothian region of central Scotland. Subjects underwent detailed cognitive
and physical examination, the latter including measures of micro- and macro-vascular disease,
glycaemic control, body fat composition and plasma inflammatory markers, cortisol, lipids and liver
function tests. Participants were re-examined after one year with hepatic ultrasonography and
additional measures of vascular disease. This paper reports the methods of recruitment to the
study and examinations performed at baseline and one year. Follow-up cognitive, vascular and liver
assessments are scheduled for 2010–2011 when subjects will have been in the study for 4 years.
Discussion: This study will provide a wealth of epidemiological and biomarker data that should be
invaluable in the identification of potentially modifiable, causal risk factors for diabetes-related
cognitive impairment, liver dysfunction and vascular disease, which can be targeted for the
development of preventive and therapeutic interventions.
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Type 2 diabetes currently affects around two million peo-
ple in the UK and approximately 10% of people aged over
65 years. The prevalence of the condition is predicted to
double over the next 20 years, with a particular increase in
elderly people [1]. Much has been done over the last dec-
ade to try to prevent and treat the well-recognised micro-
and macrovascular complications of diabetes, including
atherosclerotic cardiovascular disease, diabetic retinopa-
thy, nephropathy and peripheral neuropathy. However,
morbidity and mortality from vascular disease remains
high in older people with type 2 diabetes. In addition,
other complications of diabetes are becoming increas-
ingly evident in the ageing diabetic population. These
include the deleterious effects of type 2 diabetes on the
brain, resulting in a greater prevalence of age-related cog-
nitive impairment and an enhanced risk of age-related
cognitive decline, in addition to higher incidences of
stroke and dementia [2-4]. Non-alcoholic fatty liver dis-
ease, a disorder that encompasses a wide spectrum of
hepatic abnormality from fatty infiltration and steatosis to
steatohepatitis, fibrosis and ultimately cirrhosis, is
increasingly recognised to be associated with the diabetic
condition, potentially affecting up to 90% of people with
established type 2 diabetes [5-7]. Relatively little is known
about the risk factors associated with the development
and progression of these less prominent diabetes-related
complications, although factors such as poor glycaemic
control, increased inflammation, abnormal glucocorti-
coid metabolism and microangiopathy may be important
[8-12]. Detailed information on potential risk factors is
crucial to identify causal and modifiable risk factors that
can be targeted for the development of appropriate pre-
ventive and therapeutic interventions, in addition to help-
ing to identify patients who are at increased risk of
developing complications.
The aims of this project were:
1. To determine the association between potentially mod-
ifiable risk factors (including microvascular disease,
inflammatory mediators and hormones of the hypotha-
lamic-pituitary-adrenal (HPA) axis) and cognitive decre-
ments in people with type 2 diabetes.
2. To determine, in older people with type 2 diabetes, (i)
the prevalence of Non-Alcoholic Fatty Liver Disease
(NAFLD), (ii) clinical factors that might permit early
detection of people at increased risk of developing NAFLD
and (iii) potentially causal risk factors for the develop-
ment and progression of NAFLD.
3. To identify circulating biomarkers and other risk factors
which (i) predict the development of symptomatic and
asymptomatic micro- and macrovascular disease, (ii) are
associated with progression of these complications and/or
(iii) have a potentially causal role in their development.
4. To establish a well-characterised and compliant popu-
lation sample with extensive phenotyping and the poten-
tial for genotyping, which can be used as the sampling
frame for subsequent nested case control studies (includ-
ing neuroimaging), and as a replication population for
findings arising from genome-wide association studies.
Methods and design
The study was designed as a population-based, prospec-
tive cohort study. Ethical permission was obtained from
the Lothian Medical Research Ethics Committee.
Study Population
Sampling frame
With the permission of the Lothian Diabetes Services
Advisory Group and the Caldicott Guardian for NHS
Lothian, patients recorded as having type 2 diabetes were
selected from the Lothian Diabetes Register (LDR). The
LDR is a computerised database, which was established in
2001, and contains clinical details on over 20,000
patients with known type 2 diabetes living in Lothian,
Scotland. Comparison of age-sex specific prevalences of
diabetes recorded on the LDR with those from other data
sources in Scotland suggests that the LDR captures almost
everyone with diagnosed diabetes in Lothian (Dr Sarah
Wild, personal communication).
Confirmation of diagnosis of type 2 diabetes
Individual patients are recorded on the LDR once the
diagnosis of diabetes has been confirmed according to
WHO criteria. Further classification of the patient as suf-
fering from type 2 diabetes is made by medical staff in
individuals who are not insulin deficient (as indicated by
the presence of ketonuria or ketonaemia) and who have
no evidence of secondary diabetes (endocrinopathies or
exocrine pancreatic insufficiency) or a genetic aetiology
(e.g. Maturity Onset Diabetes of the Young). In order to
confirm the diagnosis of type 2 diabetes and exclude indi-
viduals erroneously recorded as such on the LDR, the
study team reviewed data on potential participants. For
the purposes of the present study, the diagnosis of diabe-
tes was accepted in any individual treated with oral anti-
diabetic agents and/or insulin, and in any subject treated
with dietary modification alone whose HbA1c was > 6.5%
at the research clinic. The clinical records of all subjects
treated with dietary modification alone and with an
HbA1c ≤ 6.5% at the research clinic were reviewed by a
consultant diabetologist (MS) to ensure that the diagnosis
of diabetes was robust. The clinical records of individuals
who either:(i) started on insulin within one year of diag-
nosis of diabetes, (ii) reported evidence of pancreatic sur-
gery/disease at the research clinic or (iii) were treated withPage 2 of 10
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reviewed. Such individuals were considered to be at the
greatest risk of mis-classification. Any subject in whom it
was not possible to confirm a clinical diagnosis of type 2
diabetes by review of hospital and/or GP records was
excluded.
Exclusion criteria
Other exclusion criteria were, (i) non-English speakers
(since fluent English is required for some of the cognitive
tasks), (ii) corrected visual acuity worse than 6/36 for dis-
tance vision or unable to read large print text (as at least
moderate visual function is required to complete some of
the cognitive tasks), (iii) unwilling to give consent (or
judged by clinical research staff to be unable to give fully-
informed consent) (iv) physically unable to complete the
clinical and cognitive examination.
Power and sample size
The aim was to recruit 1000 subjects in order to provide
around 90% power at the two-sided 5% level of signifi-
cance to detect a Pearson correlation coefficient of ≥ 0.10,
between continuous outcome measures (e.g. cognitive
test scores) and predictor variables. Allowing for deaths
and drop-outs during follow-up, it was estimated that a
sample size of 800 would retain 90% power to detect a
correlation coefficient of ≥ 0.12 between risk factors and
outcome measures. It was also estimated that with this
sample size and with the same levels of power and signif-
icance, it would be possible to detect any risk factor that
contributed 1% or more to the variance in outcome, both
at baseline and at follow-up.
Subject Recruitment
People aged between 60 and 74 years on 1st August 2006
were selected by sex and 5-year age bands from computer-
randomised lists of eligible subjects extracted from the
LDR. Between 20th June 2006 and 1st June 2007, 5454
invitations to participate in the study were mailed by the
custodians of the Lothian Diabetes Register. Of these, no
response was received from 2104, and a further 64 were
returned as being unknown at the address recorded on the
LDR. Of the 3286 individuals who replied, 1252
expressed interest in participating in the study (Figure 1).
Another randomly selected subject from the same sex and
5-year age band replaced subjects not replying to the invi-
tation letter or refusing to participate. To preserve patient
confidentiality, only the names and addresses of subjects
who expressed interest in participating were forwarded to
the ET2DS team, precluding follow-up of individual non-
responders. Each person expressing an interest in the
study was sent an appointment for the research clinic,
together with a questionnaire to be completed and
returned to the research team. Strenuous efforts were
made to ensure that anyone agreeing to participate was
actually assessed, including payment of travel expenses,
provision of transport to and from the clinic if required, a
choice of days to attend the clinic, multiple contact
attempts from the ET2DS team by both telephone and
mail, and reminder telephone calls on the day preceding
clinic appointments. Of the 1252 subjects who expressed
interest, 1077 attended the baseline research clinic: the
ET2DS team were unable to re-contact 56 individuals, 111
were unable or unwilling to attend for clinical examina-
tion when invited, five repeatedly failed to attend their
research clinic appointment and three had died. Of the
1077 subjects attending the baseline clinic, four were sub-
sequently excluded from the study because they were una-
ble for physical or emotional reasons to complete the
cognitive or physical examinations. In addition, seven
subjects were excluded as they did not meet the criteria for
type 2 diabetes after detailed review of hospital and pri-
mary care notes, searching of electronic databases and,
where necessary, discussion with the general practitioner.
Of these seven subjects, two diet-treated patients with
HbA1c < 6.5% at the research clinic could not be con-
firmed as having diabetes (from a total of 70 subjects who
were reviewed for this reason), four subjects were felt to
have type 1 diabetes (from a total of 25 subjects reviewed
due to starting on insulin within 1 year of diagnosis or
being treated with insulin and diagnosed under the age of
35 years), and one subject had a previous pancreatic neu-
roendocrine tumour (from a total of 11 subjects reviewed
due to reporting prior pancreatic disease). This left 1066
subjects who were both willing and eligible to take part in
the ET2DS (Figure 1).
Schedule of data collection (Figure 2)
Baseline visit
At baseline and following an overnight fast, all subjects
attended a dedicated research clinic where they gave writ-
ten informed consent for participation in the study. Each
subject provided a urine specimen, underwent venepunc-
ture, and, following breakfast, completed a cognitive and
physical examination (predominantly for cardiovascular
risk factors and vascular disease). The physical examina-
tion was undertaken by one of six specially trained
research nurses and measurement technicians, using pre-
specified standard operating procedures and a specially
designed form for data collection. Subjects also returned
their completed questionnaires, including questions on
demographic characteristics, educational attainment, dia-
betes history and treatment, cardiovascular disease and
other co-morbidities, medications, alcohol intake, smok-
ing habits, employment/occupation, stress, satisfaction
with life, subjective social status and personality. Approx-
imately two to three weeks after their initial visit, subjects
returned to a separate research clinic for digital retinal
photography.Page 3 of 10
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Recruitment and participation in the Edinburgh Type 2 Diabetes Study (baseline and year 1 examinations)Figure 1
Recruitment and participation in the Edinburgh Type 2 Diabetes Study (baseline and year 1 examinations).
 
Invited 
n = 5454 
Replied 
n = 3286  
No response (n=2104) 
Moved address (n=64) 
Not interested in participation 
(n = 2034) 
Interested in 
participation 
n = 1252  
Attended baseline clinic 
n = 1077  
ET2DS participants
n = 1066 
Failed to meet inclusion criteria 
(i) unable to complete cognitive/physical 
examination (n= 4) 
(ii) not type 2 diabetes (n=7) 
Did not attend baseline clinic 
(i) unable/unwilling to attend (n=111) 
(ii) could not be contacted (n=56) 
(iii) repeatedly failed to keep appointment (n=5) 
(iv) deceased (n=3) 
Invited to attend one  
year clinic 
n = 1054 
Not invited to one year clinic 
(i) known to have died (n=2) 
(ii) refused consent to be contacted for 
examinations other than baseline and 4 year 
follow-up (n=5) 
(iii) deemed unsuitable for contact by study 
team (n=3) 
(iv) withdrew from any further contact after 
baseline examination (n=2) 
Attended one year clinic 
n = 940  
Did not attend one year clinic 
(i) unable to contact subject (n=19) 
(ii) unable/unwilling to attend on health grounds 
(n=23) 
(iii) unable/unwilling to attend for non health 
related reason (n=38) 
(iv) cancelled/did not attend appointment (n=21) 
(v) dead (n=13)  
Failed inclusion criteria 
(i) unable to complete examination (n=1)  
One year clinic 
participants 
n = 939
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Data collection at baseline and one year research clinics in the Edinburgh Type 2 Diabetes StudyFigure 2
Data collection at baseline and one year research clinics in the Edinburgh Type 2 Diabetes Study.
Baseline clinic 
(cognitive and physiological testing) 
Cognitive and mood testing  
    Battery of neuropsychological tests 
    Mill Hill Vocabulary Scale 
    Hospital Anxiety and Depression Scale 
Physical examination 
    Blood pressure 
    BMI, WHR, % body fat 
    ECG 
    Ankle brachial index 
    Neurothesiometry  
Questionnaire (including WHO Chest Pain    
    and Edinburgh Claudication Questionnaires  
Blood sample 
    Inflammatory markers 
    Cortisol 
    Lipids 
    Blood glucose, HbA1c 
    Liver function tests 
    Hyaluronic acid 
Urinary albumin/creatinine ratio 
Baseline Clinic 
(digital retinal photography) 
Diabetic retinopathy 
One year clinic 
Questionnaire including sleep apnoea  
     questionnaires 
Abdominal USS 
Carotid IMT and plaque measurement 
Pulse wave analysis and velocity 
Hypoglycaemia questionnaire 
‘Routine’ data collection 
ISD SMR01 data  
   Medical and surgical discharges   
   from Scottish hospitals  
LDR data  
   HbA1c, blood pressure,  
   cholesterol 
2-3 weeks 
1 year 
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At baseline, data were collected for all participants on dis-
charges from non-psychiatric, non-obstetric wards in
Scottish hospitals between 1981 and September 2007
using record linkage to the SMR01 scheme (acute hospital
admissions) at the Information and Services Division of
NHS Scotland [13]. These data were used to supplement
self-reported history of cardiovascular disease, liver condi-
tions and diabetic complications. Selected primary and
secondary care data held on the Lothian Diabetes Register
(LDR) were also retrieved for participants to provide serial
historical data for key biochemical and clinical variables,
such as HbA1c, blood pressure and serum cholesterol lev-
els. Non-identifiable data on non-participants were also
collected from the LDR, to enable comparison of charac-
teristics with study participants and therefore assess the
representativeness of the study population.
One year visit
All participants who were alive and who had consented
(at baseline) to be contacted about additional studies,
were invited to return for a further examination, one year
after their recruitment into the study. This visit was prima-
rily for hepatic assessment, including abdominal ultra-
sound examination, but also enabled further vascular
phenotyping (carotid intima media thickness (IMT),
carotid plaque assessment, pulse wave velocity and analy-
sis). A total of 940 subjects attended for this examination.
Of the remaining 126 original ET2DS participants, 17 had
died or had withdrawn from further contact since base-
line, 8 had either indicated that they did not wish to be re-
contacted for this examination when seen at baseline or
were deemed unsuitable for contact by the study team, 61
were unable or unwilling to attend when contacted by let-
ter and/or telephone and 40 either could not be contacted
or did not attend their clinic appointment (Figure 1). In
addition to the abdominal ultrasound, vascular examina-
tions and venous blood sampling, all of which were per-
formed after a fast of at least four hours, a second
questionnaire was completed, including updated ques-
tions on alcohol intake, medications and history of liver
disorder, Berlin and Epworth sleep apnoea questionnaires
[14,15], and questions relating to diabetes healthcare pro-
vision in Lothian. Subjects were also provided with short
self-assessment questionnaires on which to record the
occurrence of severe hypoglycaemic episodes over the
subsequent six months.
Cognitive testing
At baseline, a battery of psychometric tests, which pro-
vides a comprehensive and validated assessment of cogni-
tive functions and mood states, was administered.
Individual testers were trained and then observed for val-
idation by one investigator (ID). Executive function was
assessed with the Borkowski Verbal Fluency Test (VFT),
which requires participants to generate as many words as
possible with a specified initial letter (C, F and L), within
a one minute period for each letter (proper nouns disal-
lowed and repeated words scored only once) [16]. Imme-
diate and delayed verbal declarative memory was assessed
using a participant's score on the Logical Memory subtest
of the Wechsler Memory Scale 3rd Edition (WMS-IIIUK)
[17]. This involves the immediate recall of a story with 25
elements ("story units"), which is read aloud. Participants
are informed that they will be questioned about the story
again later, and delayed recall is recorded in the same way
after approximately 40 minutes. The score is based on the
number of story units recalled correctly. Non-verbal mem-
ory was assessed using the Faces subtest of the WMS-IIIUK.
Subjects are shown a series of pictures of faces and then,
in subsequent immediate and delayed tests they are asked
to select these faces from a larger series of pictures. As a
measure of mental flexibility, the Trail Making Test [18]
was administered and the time taken to complete part B
was used in the subsequent analysis. Subjects completed
several subtests of the Wechsler Adult Intelligence Scale
3rd Edition (WAIS-IIIUK) [19]. The Digit Symbol Coding
subtest was used as a measure of speed of information
processing – the number of symbols matched correctly to
their corresponding numbers in 120 seconds was
recorded. The Letter-Number Sequencing subtest was
used to assess working memory – participants listened
while the tester read mixed, and increasingly longer,
strings of numbers and letters. They repeated them to the
tester, with the numbers first, in numerical order, and
then the letters in alphabetical order. In each item of the
Matrix Reasoning subtest (non-verbal reasoning), partici-
pants examined a pattern arrayed in matrix with a piece
missing. The elements of the matrix are arrayed according
to rules. The task is to work out the rules, apply them to
find out what the missing piece should look like, and
choose the correct piece from the answer options.
All subjects were asked to complete a combined version of
the Junior and Senior Form A synonyms of the Mill Hill
vocabulary scale [20], an indicator of prior ('best ever' or
pre-morbid) cognitive ability which changes very little
with age [21,22]. Subjects were presented with a word and
asked to identify the closest synonym from six given alter-
natives. The Mini Mental State Examination [23], often
used as a 'screen' for dementia, was included as a general
mental assessment.
The Hospital Anxiety and Depression Scale (HAD A and
HAD D respectively) [24] was also used for the assessment
of mood states, which can affect performance on the cog-
nitive tests. Corrected visual acuity, near vision and capil-
lary blood glucose were also measured before proceeding
to cognitive testing. A blood glucose > 4 mmol/l wasPage 6 of 10
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for cognitive testing.
Assessment of macrovascular disease and cardiovascular 
risk factors
Questionnaire
In the questionnaire applied at baseline, participants
answered questions on medical diagnoses and/or treat-
ment (medical or surgical) for angina, coronary heart dis-
ease/myocardial infarction, stroke, peripheral arterial
disease, carotid stenosis, hypertension and hypercholes-
terolaemia. Details on the year of diagnosis or event, and
hospital or general practice attended, were collected to
enable further validation of diagnoses after comparison
with ISD and LDR data. Subjects also completed a stand-
ard smoking history questionnaire and the WHO Chest
Pain [25] and Edinburgh Claudication Questionnaires
[26].
Physical examination
Systolic and diastolic brachial blood pressures were meas-
ured in the right arm to the nearest 2 mmHg with subjects
in the supine position and with the arm resting at the level
of the mid-sternum, using a standard stethoscope and an
aneroid, 6 inch dial, desk standing sphygmomanometer
(Acceson™, AC Cossor & Son (Surgical) Ltd, Harlow, UK).
To assess body mass index, standing height was measured
to the nearest mm, without shoes, using a wall-mounted
vertical rule. Weight was assessed to the nearest 0.1 kg
without outdoor clothing or shoes using SECA 761 elec-
tronic weighing scales. For waist:hip ratio (WHR), waist
circumference was measured during exhalation at the
level midway between the lower rib margin and the iliac
crest (pre-marked at the mid-axillary line on each side of
the subject), with the subject standing with their feet 30
cm apart and with their hands by their sides. Hip circum-
ference was taken with the subject in the same standing
position, by wrapping the tape measure around the but-
tocks and lowering or raising the tape until the maximum
circumference was located and the tape fitted comforta-
bly. Both measurements were made using a non-expand-
able tape measure, and the average of two readings taken
to the nearest 0.5 cm was taken as the final measurement.
Body fat percentage was taken as the average of three con-
secutive readings (to the nearest 0.1%), using an OMRON
BF306 Body Fat Monitor (OMRON Healthcare (UK) Ltd.,
Henfield, UK). The monitor was pre-set to the correct
weight, age and gender for each subject. Subjects stood
with their feet 30 cm apart, with their arms at 90° to their
trunk and with the palms of each hand placed firmly on
the top and bottom electrodes.
A resting 12-lead electrocardiogram was recorded accord-
ing to standard procedures (Marquette MAC 1200
machine) and coded using the Minnesota coding system
by clinical members of the research team http://
www.epi.umn.edu/ecg/ (MS, RR, RW). Right and left bra-
chial, posterior tibial and dorsalis pedis systolic pressures
were recorded with the subject in the supine position and
after at least 5 minutes rest, using the aneroid sphyg-
momanometer and a doppler probe (Dopplex® advanced
pocket Doppler, Huntleigh Healthcare Ltd., Cardiff, UK).
The ankle brachial pressure index (ABI) was calculated for
each subject by dividing the lowest of the ankle pressures
by the higher of the two arm pressures. To assess inter-
observer variation in ABI (and WHR), a total of 20 sub-
jects had repeat measurements of waist and hip circumfer-
ences and ankle and brachial pressures, done on a single
day by all six of the clinic staff, independently.
Bilateral carotid IMT was measured in the supine position
with the neck extended and the chin turned contralateral
to the side being examined. A Sonoline Elegra Ultrasound
Imaging System (Sieman's Medical Systems Inc, Washing-
ton, USA), software version 6, was used. A high frequency
linear transducer (8–12 MHz), set up for maximum reso-
lution, was orientated so that the back wall of the com-
mon carotid artery was parallel to the transducer face and
a double line was clearly seen. IMT was measured on the
far wall of the artery, 1–2 cm below the carotid bifurcation
and in an area free of plaque. The mean of three measure-
ments (to the nearest 0.1 mm) from three separate images
was taken. A longitudinal image was also stored for subse-
quent off-line serial IMT measurements. The common,
internal and external carotid arteries were examined for
the presence or absence of plaque. Plaque was defined as
a focal structure encroaching into the arterial lumen of at
least 0.5 mm or 50% of the surrounding IMT value, or
with a thickness > 1.5 mm as measured from the media-
adventitia interface to the intima-lumen interface. Plaque
at, or within 2 cm, of the bifurcation was recorded bilater-
ally, together with the maximum thickness of the plaque
and the presence or absence of echoluscent plaques. Echo-
luscent plaque was recorded where one or more plaques
appeared as black or almost as black as flowing blood
(compared with echogenic plaque which appeared white
or almost white, similar to the far wall media-adventitia
interface). The presence of heterogeneous plaque was
recorded if there were one or more plaques in which echo-
genicity of more than 20% of the plaque area differed sub-
stantially from the echogenicity of the rest of the plaque.
Video images were stored for further assessment, includ-
ing grading of echogenicity.
Pulse wave analysis and velocity are established measures
of arterial stiffness whose measurement is increasingly
standardised [27]. Measurements were performed after
subjects had been supine for at least 25 minutes. Systolic
and diastolic brachial blood pressures were measured
twice using either the aneroid, 6 inch dial, desk standingPage 7 of 10
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(W.B.I.C, Wenzhou, China) and the mean of each taken.
All measurements were taken from the left arm unless this
was undesirable or impossible (e.g. previous stroke or
amputation affecting left arm) in which case the right side
was used. Pulse wave analysis was determined by applana-
tion tonometry of the radial, carotid and femoral arteries
using a high-fidelity micromanometer (SPT-301B; Millar
Inc, Texas, USA) and the SphygmoCor™ system 8.0 ver-
sion (AtCor Medical Pty Ltd, New South Wales, Australia).
Data from the radial artery pulse wave were collected
directly into a computer and, after 10 seconds of sequen-
tial waveforms had been acquired, an averaged peripheral
waveform was generated. A corresponding averaged cen-
tral pressure waveform was then generated, using a vali-
dated transfer function. From this, central augmentation
index (both unadjusted and adjusted to a standard heart
rate of 75 bpm) and central aortic blood pressure were
determined using the integral software. For measurement
of pulse wave velocity the arterial pulse waveform was
recorded as above at the common carotid and femoral
arteries. The time delay between the arrival of the foot of
the pulse wave at the two points was obtained by gating to
the peak of the R-wave on electrocardiogram. Separation
of the pulse waveforms was defined as the difference
between the distances from the sternal notch to the
carotid measurement site and from sternal notch to the
femoral measurement site. Pulse wave velocity was calcu-
lated as distance/time (m/s). All measurements were
made in duplicate and the mean values calculated. If there
was variation in the augmentation index of greater than
5% or in pulse wave velocity of greater than 0.5 m/s, a
third reading was obtained if possible. If the latter was
within 5% or 1.0 m/s of one of the first readings then the
mean of these was used; otherwise the mean of all three
readings was used. If only one reading was obtained then
this alone was used.
Assessment of microvascular disease
Assessment of diabetic retinopathy by digital retinal pho-
tography was used as the most sensitive and specific meas-
ure of generalised microvascular disease. Standard 7-field
digital retinal colour photographs of both eyes were taken
at 45% by a single specially trained medical photogra-
pher, following pupillary dilatation and using a high res-
olution digital retinal camera (TOPCON TRC-50FX).
Retinopathy was graded using the Early Treatment of Dia-
betic Retinopathy Scale modification of the Airlie House
Classification scheme, which assesses the level of retinop-
athy for each eye [28,29]. This grading system has been
used extensively in clinical and epidemiological studies of
diabetic retinopathy, including the Diabetes Control and
Complications Trial and the UK Prospective Diabetes
Study, to assess baseline status of retinopathy and progres-
sion of disease. Two dedicated optometrists graded
images independently and discrepancies in coding
between the graders were resolved in the first instance by
discussion between the graders. Unresolved discrepancies
at this point were reviewed and arbitrated upon by a con-
sultant ophthalmologist.
Assessments of peripheral neuropathy and nephropathy
were undertaken as secondary measures of microvascular
disease. Hand-held neurothesiometer readings were taken
from the apex of the big toe (Horwell Neurothesiometer,
Scientific Laboratory Supplies Ltd, Nottingham, UK), with
subjects sitting or lying, feet elevated and eyes closed. Fol-
lowing a test procedure on the subject's hand, the mini-
mum vibration threshold at which the subject was aware
of vibration sensation was recorded to the nearest 0.5
volts. The means of three recordings from each foot were
taken as the final measurements. Albuminuria was meas-
ured using the urinary albumin/creatinine ratio in an
early-morning specimen of urine.
Liver assessment
At baseline, liver function was assessed by measurement
of plasma liver function tests (LFTs) (details below) and
hyaluronic acid. In addition a full history of previous liver
disease, alcohol intake and use of prescription medica-
tions was obtained by questionnaire. At one year, LFTs
were repeated, history was updated by questionnaire and
a more detailed examination was undertaken using ultra-
sonography. All ultrasound examinations were performed
by a single ultrasonographer who was unaware of the clin-
ical and laboratory results of the participants, on a Sono-
line Elegra Ultrasound Imaging System (Sieman's Medical
Systems Inc, Washington, USA), software version 6, using
a 3.5 MHz transducer. A phantom (411 LE 0.5, GAMMEX
rmi Ltd, Nottingham, UK) was scanned multiple times
using the different pre-sets prior to the study to ensure
continuity of image contrast at follow-up and the appro-
priate pre-set was chosen for each subject and noted on
the ultrasound data collection sheet. Three graders (one
sonographer, one specialist registrar in radiology and one
consultant radiologist) independently graded the liver for
evidence of fatty infiltration using accepted criteria includ-
ing a bright hepatic echo pattern (compared with the right
kidney), increased attenuation of the echo beam and loss
of intrahepatic architectural details. Participants received
an overall grading of "normal", "indeterminate", "mildly
fatty" or "severely fatty". Evidence of more advanced
forms of liver disease, including cirrhosis and features of
portal hypertension was also sought systematically. In
addition the gallbladder, common bile duct, spleen, pan-
creas, kidneys and aorta were examined. A subgroup of 60
subjects with the full range of liver ultrasound findings
underwent detailed magnetic resonance imaging and
spectroscopy to quantify liver fat and help validate the
ultrasound findings.Page 8 of 10
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logical assessment to investigate causes of abnormal liver
function, including hepatitis B and C serology, ferritin,
anti-smooth muscle and anti-mitochondrial antibodies,
anti-nuclear factor and alpha fetoprotein. Individuals
with abnormal tests and/or significant derangement of
liver function were referred to a specialist hepatology
clinic for further investigation and management.
Blood samples
At baseline, venous blood sample were taken after an
overnight fast for DNA extraction, white blood cell
immortalisation, measurement of plasma c-reactive pro-
tein, fibrinogen, interleukin-6, tissue necrosis factor-α,
cortisol and cortisol binding globulin, creatinine, eGFR,
total cholesterol, high density lipoprotein cholesterol,
blood glucose, HbA1c, total protein, aspartate amino
transferase, alanine amino transferase, alkaline phos-
phatase, gamma glutamyl transferase, bilirubin, albumin,
full blood count and hyaluronic acid. At one year, venous
blood samples were taken (after a four-hour fast) for uric
acid, total cholesterol, low and high density lipoprotein
cholesterol, triglycerides, plasma glucose and repeat LFTs
and HbA1c. At both baseline and 1 year, plasma was
stored for future biomarker measurements.
Data entry, checking and storage
Data from the baseline questionnaire and data collection
forms were coded and entered onto a master Microsoft
Access database. The results of plasma assays were entered
onto the same master database, either from paper records
(biochemistry and haematology) or from electronic files
provided by the participating laboratories. For retinopa-
thy grading, data on individual retinal characteristics for
each relevant photographic field were entered directly
onto a specially designed spreadsheet (Microsoft Excel).
The overall retinopathy grade for the right and left eyes for
each subject was calculated automatically and these
results were transferred to the master database. The major-
ity of data from paper records were double entered and
discrepancies resolved by reference to the original paper
documentation. For the remaining data a random sample
of records was double-checked. A small amount of base-
line data that was found to be missing was collected at the
one year clinic (primarily clarification of incomplete or
inconsistent personal and clinical details) and used to
update the master database.
Questionnaire data and plasma assays collected at the one
year clinic visit were entered initially onto a separate
Microsoft Access database and checked for inconsistencies
prior to transfer onto the master database. Data from the
abdominal ultrasound scan, carotid IMT and assessment
of plaque were entered onto a third Microsoft Access data-
base at the time of grading and these were transferred
directly onto the master database. Pulse wave measure-
ments were exported to a Microsoft Excel file and from
there entered onto the master database.
All data, including the master database, the retinal photo-
graphs and carotid and abdominal ultrasound scans were
stored securely on dedicated university computers and
backed up on a dedicated university server.
Discussion
The Edinburgh Type 2 Diabetes Study is a large prospec-
tive cohort study that has the potential to identify factors
that are important for the development and progression
of less well-characterised complications of type 2 diabetes.
The study protocol is being reported at the point at which
baseline and one year data have been collected and
checked. Analyses are currently underway on this rich
dataset to address the objectives described in this report.
Further analyses to fully meet these objectives will be con-
ducted after the follow-up assessments of cognitive func-
tion, vascular parameters and liver structure and function
have been completed in 2010–11.
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